ABSTRACT
The COVID-19 pandemic exhibits stark social inequities in infection and mortality outcomes. We investigated neighborhood-level inequities across cities in the US and Canada for COVID-19 cumulative case rates (46 cities), death rates (12 cities), testing rates and test positivity (12 cities), using measures that characterize social gradients by race/ethnicity, socioeconomic composition, or both jointly. We found consistent evidence of social gradients for case, death and positivity rates, with the most privileged neighborhoods having the lowest rates, but no meaningful variation in the magnitude of inequities between cities. Gradients were not apparent in testing rates, suggesting inadequate testing in the most deprived neighborhoods. Health agencies should monitor and compare inequities as part of their COVID-19 reporting practices and to guide pandemic response efforts.
HIGHLIGHTS
Within urban regions with available data in the US and Canada, there were strong social gradients for case, death and positivity rates
The most racially and/or economically privileged neighborhoods had the lowest rates
Social gradients were similar for neighborhood-level measures of racial/ethnic composition, income, racialized economic segregation, and racialized occupational segregation
Testing rates did not show consistent social gradients, which suggests that the most deprived neighborhoods have inadequate access to testing relative to their higher disease burden
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study received no external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Neither approval nor exemption by an IRB/REB was required because the study only used public-use data that does not allow identification of individuals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data, code, and additional visualizations available at: https://ssaha.shinyapps.io/COVID_cities_inequities
